Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RVPH 
Reviva Pharmaceuticals Holdings Inc. (RVPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/11/2025: RVPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.38
1 Year Target Price $5.38
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.57% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 62.73M USD | Price to earnings Ratio - | 1Y Target Price 5.38 |
Price to earnings Ratio - | 1Y Target Price 5.38 | ||
Volume (30-day avg) 6 | Beta -0.04 | 52 Weeks Range 0.25 - 2.99 | Updated Date 11/11/2025 |
52 Weeks Range 0.25 - 2.99 | Updated Date 11/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date 2025-11-17 | When - | Estimate -0.108 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -173.7% | Return on Equity (TTM) -916.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47267971 | Price to Sales(TTM) - |
Enterprise Value 47267971 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6 | Shares Outstanding 114078619 | Shares Floating 65522161 |
Shares Outstanding 114078619 | Shares Floating 65522161 | ||
Percent Insiders 4.33 | Percent Institutions 12.14 |
Upturn AI SWOT
Reviva Pharmaceuticals Holdings Inc.
Company Overview
History and Background
Reviva Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. Founded in 2006, it went public in 2020 through a merger. They've focused on advancing their lead drug candidate, Brilaroxazine.
Core Business Areas
- CNS Drug Development: Development and commercialization of novel therapies for central nervous system (CNS) disorders.
Leadership and Structure
Laxminarayan Bhat, Ph.D., is the President, CEO, and Chairman. The company has a typical structure for a biotech firm, with departments for research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Brilaroxazine: A novel drug candidate being developed for schizophrenia, bipolar disorder, and pulmonary arterial hypertension (PAH). It is currently in clinical trials. No market share yet as it's not approved. Key competitors for schizophrenia and bipolar disorder include: Janssen (INVEGA Sustenna), Otsuka (Abilify Maintena), Alkermes (Aristada).
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, driven by the increasing prevalence of mental health disorders and an aging population. It is also heavily competitive and regulated.
Positioning
Reviva is a smaller player trying to gain market share with a novel mechanism of action for schizophrenia and bipolar disorder. Their competitive advantage lies in the potentially improved efficacy and safety profile of Brilaroxazine.
Total Addressable Market (TAM)
The global market for schizophrenia and bipolar disorder therapeutics is estimated to be in billions of dollars. Reviva is positioned to capture a portion of this TAM if Brilaroxazine is approved and successful. The PAH market is smaller.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action
- Potential for improved efficacy and safety compared to existing treatments
- Experienced leadership team
- Focus on unmet needs in CNS disorders
Weaknesses
- Lack of approved products and revenue
- Dependence on successful clinical trials
- Limited financial resources compared to larger competitors
- High risk associated with drug development
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- FDA approval and commercialization of Brilaroxazine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
- Adverse safety events
Competitors and Market Share
Key Competitors
- JNJ
- OTSKY
- ALKS
- TEVA
- MYL
Competitive Landscape
Reviva faces intense competition from larger, established pharmaceutical companies. Their success depends on demonstrating the superiority of Brilaroxazine. They have to out-compete generics such as TEVA and MYL while making a novel drug that is better than established drugs (JNJ, OTSKY, ALKS)
Growth Trajectory and Initiatives
Historical Growth: As a development-stage company, Reviva's growth is tied to the progression of Brilaroxazine through clinical trials.
Future Projections: Future projections are dependent on clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Focus on completing ongoing clinical trials for Brilaroxazine in schizophrenia and bipolar disorder.
Summary
Reviva Pharmaceuticals is a high-risk, high-reward biopharmaceutical company. The company has a novel drug in development that could address unmet needs. Clinical trial success is critical to their future but the company needs to watch out for larger competitors. The company's limited resources may also hinder its ability to effectively compete.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Reviva Pharmaceuticals Holdings Inc.
Exchange NASDAQ | Headquaters Cupertino, CA, United States | ||
IPO Launch date 2018-10-18 | Founder, CEO, President & Director Dr. Laxminarayan Bhat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.revivapharma.com |
Full time employees 14 | Website https://www.revivapharma.com | ||
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.